Abstract

Tissue transglutaminase (TG2) is upregulated in the pathogenesis of a wide variety of chronic diseases. In this review, special emphasis will be placed on fundamental mechanisms underlying the critical role of TG2 in fibroproliferative disorders. TG2 is best known for its cross-linking capacities in the extracellular space but has many critical and multifaceted roles beyond protein cross-linking, which are driven by the conformation and specific localization of the molecule.As extracellular cross-linker TG2 promotes fibrotic disease through the storage of latent transforming growth factor (TGF)-β1 in a stiffened extracellular matrix. As membrane-bound cell adhesion cofactor and signaling protein and intracellular cross-linker or G-protein, TG2 promotes fibrotic disease through cell survival and profibrotic pathway activation on a signaling, transcriptional, and translational level. Similarities between the roles that TG2 plays in scar tissue and in the tumor stroma suggest that a deeper understanding of key common pathways in disease pathogenesis and progression might lead to the identification of novel treatment targets and the development of new drugs and diagnostic methods.

Highlights

  • Tissue transglutaminase (TG2) is upregulated in the pathogenesis of a wide variety of chronic diseases

  • In this review special emphasis will be placed on fundamental mechanisms underlying the critical role of TG2 in fibroproliferative disorders

  • TG2 is best known for its cross-linking capacities in the extracellular space but has many critical and multifaceted roles beyond protein cross-linking, which are driven by the conformation and specific localization of the molecule

Read more

Summary

Belkin AM

8. Akimov SS, Krylov D, Fleischman LF, Belkin AM: Tissue transglutaminase is an integrinbinding adhesion coreceptor for fibronectin. 9. Wang Z, Collighan RJ, Pytel K, Rathbone DL, Li X, Griffin M: Characterization of heparinbinding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling. Wang Z, Stuckey DJ, Murdoch CE, Camelliti P, Lip GYH, Griffin M: Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective smallmolecule inhibitor. Am J Respir Cell Mol Biol 2014, 50:737–747

13. Eckert RL
Findings
44. Vogel V
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.